Current trials
Below you'll find a list of trials which are currently running at some or all of our research sites around the South Coast. If you are interested in more information about a specific trial or research in general, please contact us.
Alzheimer's disease Trials
- Connection (Medivation)
- A Global Phase 3 Safety and Efficacy Study of Oral Dimebon in Patients with mild-to-moderate Alzheimer's Disease.
- Concert (Medivation)
- A Safety and Efficacy Study evaluating Dimebon in patients with mild-to-moderate Alzheimer's Disease on Donepezil.
- SADD
- Investigating the clinical and cost effectiveness of two different classes of antidepressants, SSRI and NASSA (sertraline and mirtazapine, respectively) against placebo treatment in treating patients with depression and dementia.
- DOMINO
- Examining whether pharmacological treatment with Donepezil alone or Memantine alone is better than placebo at maintaining cognitive function in moderate to severe Alzheimer’s disease. It will also consider whether there are synergistic effects of the two drugs combined, compared with each drug alone.
- DeNDRoN 022 and DeNDRoN 023
- To demonstrate an advantage of the efficacy of multiple doses of intravenous administration of Bapinuzumab compared to placebo in patients with mild to moderate Alzheimer’s disease.
- DeNDRoN 018 BRAINz (closed to recruitment)
- This is a trial assessing the safety and efficacy of a monthly subcutaneous ZT-1 implant in improving cognition, behavioural and overall outcome, compared to oral daily doses of Donepezil.
- DeNDRoN 009 SIROCCO (closed to recruitment)
- A proof of concept study examining the efficacy of AZD3480, a nicotinic (alpha4beta2) receptor agonist, in improving cognition in patients with mild or moderate Alzheimer’s disease, compared with placebo and Donepezil.
Parkinson's disease Trials
- Pitstopp
- Promoting Independent Transfers: The Southampton Trial of Physiotherapy for Parkinson’s Disease (PIT:SToPP).
- PD Gen
- Parkinson’s Disease DNA Bank.
- PD Med
- A large randomised assessment of the relative cost–effectiveness of different classes of drugs for Parkinson’s Disease.
- DeNDRoN 012
- A multi–center, placebo–controlled, double–blind trial to examine the safety and efficacy of ACP-103 in the treatment of psychosis in Parkinson’s disease.
Other Neurodegenerative diseases
- MND Biobank
- Creation of a national DNA and cell line repository for functional genomic research into the aetiopathogenesis of motor neurone disease (MND).
- CUPID
- Cannabinoid use in progressive inflammatory brain disease (CUPID). Randomised double blind, placebo–controlled, multi–centre, parallel group study.
- EURO HD Registry: An Observational Study of the European Huntington–Disease Network (EHDN)
- View a presentation by Jenny Naji from Cardiff University. This presentation shows sites in the South West but we are also establishing sites in Poole, North Dorset and Southampton.
Further information
For more information about these trials please visit the UK Clinical Research Network website or contact us. If you would like to be kept updated with further information about the progress of trials and South Coast DeNDRoN please sign up for our newsletter.